Metagenomi Therapeutics, Inc. (MGX) stock intrinsic value fair value estimate & owner earnings analysis

Metagenomi is a preclinical genome-editing company. It is developing genome-editing medicines, including cardiometabolic programs with Ionis and a wholly owned program for Primary Hyperoxaluria Type 1. It has no product on the market. All of its revenue is collaboration revenue: $25.2 million in 2025, down from $52.3 million in 2024 after its Moderna agreement ended in April 2024 (the company regained rights to its base editing and PH1 programs) and after the Affini-T agreement ended. The remaining partner is Ionis Pharmaceuticals. The Ionis work is in its first wave of four cardiometabolic targets (TTR, AGT, APOC3 and one undisclosed), all still in lead optimization. What the business earns today. The company loses money and burns cash. Cash used in operations was $109.1 million in 2024 and $88.9 million in 2025, and about $40.7 million in the first half of 2026. After removing working-capital swings (mostly deferred collaboration revenue being recognized without new cash) and stock compensation, the earning power is negative: about $(2.24) per share in 2024 and $(2.28) per share in 2025. Capital spending is tiny, about $0.6 million a year. Because earning power is negative, there is no earnings stream to value, and the value of the shares comes down to how much of the cash on hand survives the burn. What the company has. Cash and marketable securities were $160.8 million at the end of 2025 and about $120.7 million at June 30, 2026, or roughly $3.20 per share on about 37.7 million shares. Management states that cash is sufficient for at least the next 12 months. The company also has a $75 million at-the-market stock sales facility, and further raises would dilute existing holders. Deferred collaboration revenue of about $11.2 million at June 30, 2026 is cash already received and will be recognized as revenue. Bear case, $0 per share. The company keeps spending at the recent pace of roughly $80 million a year. On that pace the $120.7 million lasts about a year and a half. No collaboration payment beyond what is already booked is contracted, and the Ionis programs are still in lead optimization, so nothing named and evidenced replaces the cash. Any financing at that point mainly benefits new investors, and the current shares are worth nothing. In its annual report the company also disclosed a securities lawsuit (Securities Action, No. 5:24-cv-06765) in which the plaintiffs allege misleading statements about the Moderna collaboration in the January and February 2024 IPO documents; the company has moved to dismiss, and the case could add cost in this scenario. Base case, $1.05 per share. Spending continues near the current pace for about one more year while research proceeds, cutting the cash to roughly $40 million. That is what demonstrably persists, about $1.05 per share. We give no value to the genome-editing platform, the Ionis programs or any preclinical candidate, because none has a signed payment, approval or regulatory license we can point to that would produce earnings. Bull case, $1.35 per share. Cash burn keeps falling on the pattern already seen (operating cash use fell from $109 million to $89 million and is running near $81 million annualized in 2026), so about $50 million of cash remains after the same year. Milestone payments, licensing deals or clinical success are not credited, because none is contracted. What we left out and why. Growth was credited in none of the cases. The company has not shown any repeatable, self-funded earnings process. The pipeline and the Ionis collaboration could be worth far more if they succeed, but success has not yet happened, so this valuation does not include it. Stock compensation was treated as a real cost. Lease payments were treated as ordinary operating costs. No debt is deducted. What would make this wrong. A milestone payment, a new partnership with large up-front cash, or a clinical result would raise value well above these figures. A rapid cut in spending that keeps cash intact would raise the base case. Faster spending or a stock issuance at a low price would lower it. Because the company depends on one active partner and has no product, the margin-of-safety price is set at a small fraction of the base value.